ComputerWorld AI·
As enterprises struggle to manage their AI strategies, the US AI regulatory environment is sending a wide range of contradictory signals. OpenAI’s Wednesday announcement that it will now release GPT-5.6 Sol, along with Terra and Luna, on Thursday highlights the confusion. Initially, the US government said that it was asking OpenAI to limit access to its top models, including the three releasing Thursday, to a short list of companies. OpenAI seemingly agreed and held back their general availability. But on Wednesday, OpenAI reversed its position, with a statement on X saying simply: “GPT-5.6 Sol, along with Terra and Luna, will launch publicly this Thursday. We’re expanding preview access globally now.” No details were released about the extent of the expansion. Then the White House issued a statement, a copy of which it emailed to InfoWorld, saying that the US government “did not give OpenAI a ‘green light,’ approval or clearance to release its models. No such permission is required or
Read full articleOpenAI's GPT-Live voice models could drive demand for decentralized AI compute, impacting crypto markets and reshaping AI infrastructure. The post OpenAI launches GPT-Live voice models that can listen and speak simultaneously, raising the stakes for AI infrastructure tokens appeared first on Crypto Briefing.
OpenAI's defense collaboration may accelerate AI regulation, impacting tech governance and prompting increased scrutiny of AI technologies. The post OpenAI unveils national security principles amid $200M Pentagon contract appeared first on Crypto Briefing.
The post SpaceX (SPCX) Stock Climbs as SpaceXAI-Cursor Joint AI Model Launch Approaches appeared on BitcoinEthereumNews.com. Key Highlights SpaceXAI and Cursor are set to unveil their first collaborative AI model, potentially as early as Wednesday, according to The Information The release was postponed earlier in the week to enhance performance and efficiency The new model aims to rival OpenAI’s GPT-5.5 and Anthropic’s Opus 4.8 This development precedes SpaceX’s proposed $60 billion all-stock purchase of Anysphere, Cursor’s parent company SpaceX (SPCX) became part of the Nasdaq-100 on Tuesday, marking a swift rise following its June 12 public offering, with shares trading near $151 SpaceXAI and Cursor are on the verge of unveiling their first collaborative artificial intelligence model, with the rollout potentially happening as early as Wednesday, based on reporting from The Information that referenced an internal company memo. JUST IN: SpaceXAI plans to launch its first model with Cur
The GPT-5.6 launch could redefine AI's role in research, prompting regulatory shifts and impacting AI market dynamics and enterprise adoption. The post OpenAI researchers debate GPT-5.6’s capabilities as AI intern appeared first on Crypto Briefing.
GPT-Live's real-time interaction could revolutionize human-AI communication, enhancing user experience and setting new standards for voice AI. The post OpenAI launches GPT-Live to make ChatGPT Voice feel more human appeared first on Crypto Briefing.
The loan highlights Wall Street's growing interest in AI IPOs, potentially accelerating OpenAI's market entry and influencing AI sector dynamics. The post Bank of America extends $520M loan to OpenAI amid IPO speculation appeared first on Crypto Briefing.
Did we make the wrong bet on ‘Big A.I.’?
The post Boom Times For Autoimmune Disease Therapies appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more. To get it in your inbox, subscribe here. AbbVie’s Skyrizi is on track to become the world’s second-highest selling drug, according to pharma consultants Evaluate. The Associated Press AbbVie’s Skyrizi, an injectable drug for autoimmune diseases that include psoriasis and Crohn’s disease, is expected to surpass $33 billion in revenue in 2032, making it the world’s second-biggest selling drug, according to a recent report from pharma data and consulting firm Evaluate. That puts it smack between Eli Lilly’s GLP-1 blockbusters, Mounjaro (for diabetes) and Zepbound (for weight loss). “Only autoimmune disease drugs come close to rivaling Lilly’s anti-obesity blockbusters given their potential to treat dozens of conditions driven by s
